effect
time
commun
acquir
respiratori
viru
carv
infect
allogen
hematopoiet
stem
cell
transplant
allohct
yet
unsettl
issu
evalu
issu
includ
consecut
allohct
recipi
molecularlydocu
carv
infect
first
year
transplant
studi
cohort
drawn
prospect
longitudin
survey
carv
allohct
recipi
respiratori
symptom
conduct
decemb
decemb
two
spanish
transplant
center
respiratori
virus
upper
andor
lower
respiratori
specimen
test
use
multiplex
pcr
panel
assay
studi
cohort
compris
allohct
recipi
carv
infect
episod
diagnos
first
year
allohct
overal
carv
episod
occur
within
first
month
thirti
patient
die
month
carv
detect
recipi
develop
carv
within
first
month
transplant
multivari
analysi
identifi
four
risk
factor
mortal
atg
use
part
condit
regimen
odd
ratio
confid
interv
ci
p
carv
lower
respiratori
tract
diseas
ci
p
carv
infect
within
first
month
transplant
ci
p
absolut
lymphocyt
count
ci
p
develop
carv
infect
within
first
month
associ
higher
mortal
data
support
time
carv
develop
allohct
could
major
interest
author
contribut
equal
understand
epidemiolog
time
respiratori
viru
infect
rvi
allogen
hematopoiet
stem
cell
transplant
allohct
import
appropri
prevent
strategi
effect
diagnosi
accur
risk
assess
sever
diseas
cours
andor
treatment
decis
make
individu
patient
epidemiolog
commun
acquir
respiratori
viru
carv
infect
among
allohct
close
parallel
incid
infect
commun
although
immunocompromis
patient
infect
notabl
prolong
viral
shed
higher
rate
pneumonia
late
airflow
obstruct
mortal
establish
valid
risk
factor
progress
upper
respiratori
tract
diseas
urtd
lower
respiratori
tract
diseas
lrtd
mortal
includ
recipi
age
smoke
histori
high
apach
ii
score
lymphopenia
highdos
total
bodi
irradi
highdos
steroid
presenc
copathogen
valid
risk
score
recent
propos
predict
respiratori
syncyti
viru
rsv
influenza
viru
infect
greater
accuraci
despit
suspicion
real
life
practic
time
carv
infect
allohct
could
relat
increas
sever
mortal
lack
strong
evid
support
belief
although
current
risk
score
includ
time
carv
infect
rel
time
allohct
cutoff
time
point
vari
differ
studi
immunosuppress
statu
allohct
classic
divid
preengraft
neutrophil
recoveri
earli
postengraft
engraft
day
late
postengraft
day
base
classif
sever
studi
analyz
impact
time
sever
mortal
differ
carv
type
scenario
inconsist
result
studi
use
aforement
cutoff
time
point
day
andor
day
andor
month
andor
year
stem
cell
infus
comparison
accordingli
studi
found
develop
carv
infect
within
day
transplant
link
wors
outcom
wherea
other
addit
studi
use
day
cutoff
time
could
show
signific
associ
outcom
other
observ
wors
outcom
carv
infect
occur
day
final
studi
found
carv
beyond
year
allohct
show
favor
outcom
other
summari
studi
found
effect
patient
outcom
regard
time
carv
infect
develop
due
discord
result
issu
remain
unresolv
warrant
research
herein
evalu
effect
time
carv
infect
mortal
consecut
seri
allohct
recipi
molecularlydocu
carv
infect
first
year
stem
cell
infus
prospect
observ
longitudin
epidemiolog
studi
carv
infect
adult
year
allohct
recipi
conduct
two
spanish
transplant
center
valencia
spain
cohort
compris
entir
consecut
allohct
recipi
molecularlydocu
carv
infect
prospect
screen
respiratori
virus
hospit
clinic
universitari
valencia
hcuv
decemb
may
hospit
universitari
la
fe
valencia
hlf
june
decemb
carv
survey
methodolog
previous
describ
detail
elsewher
briefli
decemb
hcuv
may
hlf
consecut
patient
urtd
andor
lrtd
symptom
encourag
undergo
detail
respiratori
viru
screen
molecular
test
prospect
record
clinic
biolog
characterist
time
carv
screen
includ
transplant
characterist
variabl
includ
immunodefici
score
index
isi
hospit
admiss
immunosuppress
drug
sign
symptom
acut
chronic
gvhd
local
ethic
committe
approv
studi
protocol
decemb
hcuv
may
hlf
implement
medic
informationeduc
recipi
caregiv
explain
detail
risk
rvi
context
immunosuppress
specif
inform
includ
descript
respiratori
symptom
merit
urgent
notif
transplant
team
recommend
concern
screen
respiratori
viru
avail
therapi
infecti
prevent
control
measur
patient
health
caregiv
appropri
precaut
infect
control
measur
prevent
carv
transmiss
allohct
recipi
respiratori
symptom
institut
center
accord
publish
guidelin
per
protocol
start
oseltamivir
allohct
recipi
influenza
infect
provid
respiratori
symptom
resolv
time
microbiolog
result
annual
influenza
vaccin
also
recommend
patient
transplant
center
month
follow
allohct
patient
moder
sever
gvhd
time
vaccin
program
receiv
gammaglobulin
antithymocyt
globulin
atg
rituximab
within
month
flu
vaccin
period
vaccin
administr
remain
physician
discret
rsv
human
parainfluenza
viru
hpiv
manag
accord
intervent
protocol
briefli
oral
ribavirin
given
load
dose
maximum
daili
dose
mgkg
resolut
respiratori
symptom
routin
prophylact
intraven
immunoglobulin
gkg
given
igg
serum
level
mgdl
ribavirin
therapi
institut
recipi
lrtd
caus
rsv
hpiv
wherea
patient
urtd
must
isi
point
andor
risk
factor
accord
guidelin
andor
present
one
coinfect
viru
es
start
ribavirin
current
studi
analyz
consecut
molecularlyproven
carv
infecti
episod
occur
first
year
allohct
recipientscarv
episod
includ
relapsefre
baselin
diseas
carv
infect
diagnosi
studi
conduct
decemb
decemb
carv
relat
complic
surviv
statu
updat
april
count
carv
episod
follow
recipi
one
carv
infecti
episod
censor
episod
time
point
follow
carv
episod
diagnosi
recipi
die
develop
one
carv
episod
count
closest
carv
episod
mortal
previou
one
censor
aliv
time
follow
carv
episod
urtd
defin
combin
upper
respiratori
symptom
rhinorrhea
sinus
otiti
pharyng
well
posit
carv
diagnosi
pcr
test
respiratori
sampl
absenc
lrtd
symptom
andor
indic
pulmonari
infiltr
chest
xray
ct
scan
radiolog
result
classifi
lrtd
possibl
probabl
confirm
previous
describ
probabl
episod
bronchoscopi
perform
patient
without
radiolog
proof
pulmonari
involv
respiratori
viru
infect
episod
defin
accord
recommend
carv
test
perform
three
rtpcr
multiplex
platform
describ
detail
elsewher
hcuv
sampl
test
rtpcr
use
luminex
xtag
rvp
fast
assay
luminex
molecular
diagnost
toronto
canada
hlf
clart
pneumovir
dna
array
assay
genomica
coslada
spain
perform
interpret
studi
period
follow
manufactur
recommend
luminex
xtag
rvp
fast
assay
detect
adenovirus
adv
human
bocaviru
hbov
human
coronaviru
cov
type
influenza
viru
influenza
virus
nonsubtypific
influenza
b
viru
human
metapneumoviru
hmpv
b
hpiv
rsv
ab
enterovirusrhinoviru
evrh
clart
pneumovir
dna
array
assay
differ
luminex
xtag
rvp
fast
assay
detect
influenza
c
viru
allow
detect
alphacoronaviru
viru
betacoronavirus
clart
pneumovir
abl
discrimin
rhinoviru
enteroviru
genu
permit
identif
new
influenza
hlf
juli
onward
carv
screen
allohct
recipi
perform
biofir
filmarray
respiratori
panel
biofir
diagnost
biomerieux
compani
salt
lake
citi
ut
abl
detect
respiratori
virus
influenza
viru
type
b
c
influenza
subtyp
adv
hcov
hmpv
evrh
hpiv
type
rsv
also
detect
three
bacteria
mycoplasma
pneumonia
chlamydia
pneumonia
bordetella
pertussi
primari
object
studi
assess
allcaus
mortal
time
carv
diagnosi
accord
time
carv
infect
first
year
allohct
secondari
endpoint
includ
identifi
risk
factor
allcaus
mortal
overal
surviv
os
frequenc
compar
use
test
fisher
exact
test
categor
variabl
differ
median
compar
use
mannwhitney
u
test
univari
multivari
analys
clinic
biolog
variabl
associ
allcaus
mortal
calcul
use
logist
regress
model
multivari
analysi
variabl
paramet
estim
show
p
valu
univari
analysi
final
includ
twosid
exact
p
valu
report
p
valu
consid
statist
signific
probabl
os
accord
time
carv
infect
estim
time
carv
detect
use
kaplanmei
curv
univari
comparison
made
logrank
test
data
analyz
spss
version
statist
packag
overal
allohct
recipi
develop
episod
upper
andor
lower
respiratori
symptom
screen
carv
among
allohct
recipi
develop
least
one
episod
molecularli
document
carv
account
carv
infect
episod
sixyear
studi
period
exclud
episod
occur
baselin
diseas
relaps
overal
consid
allohct
recipi
consecut
molecularlydocu
carv
infecti
episod
studi
purpos
exclud
carv
episod
occur
first
year
transplant
includ
allohct
recipi
develop
first
carv
infect
episod
beyond
first
year
transplant
final
includ
allohct
recipi
develop
molecularli
document
carv
infect
first
year
allohct
clinic
transplant
characterist
seri
detail
tabl
studi
popul
compris
highrisk
cohort
sinc
recipi
allograft
altern
donor
adult
unrel
donor
urd
singl
cord
blood
unit
haploident
famili
donor
human
leukocyt
antigen
hla
mismatch
donor
recipi
consid
high
resolut
type
hla
b
c
repres
cohort
sixtyon
recipi
receiv
atg
urdrecipi
hla
mismatch
n
cord
blood
transplant
n
hlaident
sibl
context
clinic
trial
n
carv
episod
diagnos
median
day
stem
cell
infus
rang
day
twohundr
thirtysix
carv
episod
limit
urtd
wherea
lrtd
involv
possibl
lrtd
proven
lrtd
tabl
summar
common
carv
type
isol
correspond
rate
urtd
lrtd
order
identifi
critic
period
carv
infect
sever
analyz
characterist
mortal
rate
accord
time
diagnosi
one
first
month
transplant
shown
fig
carv
episod
occur
within
first
month
particularli
month
transplant
carv
lrtd
also
commonli
observ
within
first
month
likewis
perceiv
allcaus
mortal
rate
cluster
mainli
first
month
transplant
current
seri
death
also
observ
analyz
differ
carv
type
without
statist
signific
differ
mortal
see
tabl
fact
death
detect
evrh
develop
respiratori
viru
infect
within
first
month
transplant
also
case
death
rsv
three
case
influ
three
five
piv
three
case
hmpv
case
hcov
adv
case
light
observ
choos
month
optim
cutoff
time
comparison
purpos
patient
clinic
biolog
characterist
accord
whether
carv
infect
develop
earlier
later
month
transplant
summar
tabl
expect
group
develop
carv
infect
first
month
significantli
higher
incid
sever
immunosuppressionrel
factor
use
hlamismatch
donor
isi
score
variabl
lymphopenia
logist
regress
univari
multivari
analys
risk
factor
allcaus
mortal
carv
infect
episod
lrtd
shown
tabl
studi
evalu
recipientepisod
pair
identifi
transplant
carv
condit
associ
mortal
multivari
analysi
identifi
four
rf
use
atg
part
condit
regimen
ci
analyz
episod
carv
involv
lrtd
determin
risk
factor
mortal
case
n
multivari
analysi
identifi
three
independ
factor
associ
mortal
atg
earli
carv
infect
within
first
month
associ
higher
mortal
ci
p
ci
p
respect
final
highrisk
isi
categori
also
associ
higher
probabl
mortal
ci
p
develop
carv
within
first
month
transplant
neg
effect
os
month
carv
diagnosi
os
earli
carv
infect
episod
vs
late
carv
infect
p
os
significantli
lower
allohct
recipi
earli
carv
lrtd
late
carv
lrtd
vs
respect
p
fig
b
fifteen
recipi
die
day
carv
diagnosi
six
addit
recipi
die
day
wherea
nine
recipi
die
day
carv
diagnosi
observ
signific
differ
among
caus
death
accord
time
death
carv
detect
eight
recipi
urtd
lrtd
die
respect
three
one
five
twelv
five
five
recipi
urtd
lrtd
die
day
respect
howev
median
time
carv
detect
death
among
recipi
urtd
lrtd
statist
differ
day
vs
day
p
respect
caus
death
recipi
die
day
respiratori
failur
due
mono
coinfect
n
includ
viral
bacteri
andor
fungal
coinfect
steroidsrefractori
gvhd
n
posttranspl
lymphoprolif
diseas
n
baselin
diseas
progress
n
addit
six
death
occur
day
due
respiratori
failur
context
pulmonari
mono
coinfect
n
steroidsrefractori
gvhd
n
diseas
relaps
n
remain
nine
patient
die
day
carv
detect
caus
death
infecti
respiratori
failur
n
steroidsrefractori
gvhd
n
diseas
relaps
n
pulmonari
malign
n
studi
show
time
carv
infect
first
year
allohct
could
one
major
determin
mortal
irrespect
carv
type
multivari
model
show
allcaus
mortal
month
carv
detect
significantli
higher
recipi
develop
carv
infect
within
first
month
transplant
addit
found
atg
use
part
condit
regimen
lrtd
lymphopenia
l
also
associ
higher
risk
mortal
risk
factor
mortal
among
carv
lrtd
episod
includ
earli
carv
lrtd
within
first
month
atg
part
condit
regimen
highrisk
isi
categori
sever
studi
look
effect
mortal
carv
infect
occur
allohct
use
heterogen
cutoff
time
point
show
discrep
result
fact
unabl
find
associ
time
mortal
contrast
detail
analysi
allcaus
mortal
conduct
monthli
first
year
reveal
death
occur
recipi
develop
carv
infect
within
first
month
transplant
see
fig
confirm
observ
multivari
model
includ
month
variabl
optim
cutoff
time
point
overal
carv
lrtd
differ
observ
studi
other
could
explain
two
issu
first
risk
select
bia
inher
retrospect
studi
inclus
sever
case
time
transplant
power
detect
differ
mortal
accord
time
carv
infect
sever
case
like
limit
second
common
cutoff
time
point
use
comparison
prior
report
day
vs
day
vs
day
day
transplant
select
interv
compar
overlap
month
cutoff
may
distort
effect
time
mortal
prior
studi
howev
find
suggest
aforement
cutoff
time
point
probabl
optim
enough
differenti
mortal
risk
fact
explor
cutoff
time
point
cohort
observ
statist
differ
term
mortal
best
knowledg
one
studi
focus
paramyxoviru
carv
infect
includ
cutoff
month
analysi
mortal
found
statist
signific
differ
predict
result
sinc
cutoff
correspond
anticip
length
immunosuppress
allohct
recipi
given
inclus
sever
carv
type
current
studi
could
argu
confound
find
also
independ
analyz
effect
time
carv
across
entir
cohort
observ
time
report
consist
across
carv
type
except
hbov
see
tabl
pool
analysi
differ
carv
justifi
fact
sever
prior
studi
compar
mortal
andor
os
accord
carv
type
show
signific
differ
find
underscor
need
prospect
studi
analyz
detail
effect
time
carv
infect
mortal
allohct
recipi
elucid
could
utmost
import
diagnost
purpos
infecti
control
measur
close
monitor
recipi
develop
carv
infect
within
first
month
transplant
addit
time
confirm
major
predict
factor
carv
sever
certainli
rais
unansw
question
wellestablish
clinic
andor
biolog
risk
factor
andor
immunodefici
score
reliabl
predict
mortal
due
later
develop
carv
transplant
best
except
influenza
viru
extend
rsv
current
urgent
need
new
effect
antivir
drug
carv
type
although
mani
molecul
develop
meantim
effort
focus
time
microbiolog
diagnost
prevent
carv
transmiss
particular
first
month
transplant
medic
educationinform
emphas
symptom
report
immedi
transplant
team
urgent
clinic
evalu
risk
stratif
within
h
start
respiratori
symptom
rapid
applic
sensit
diagnost
test
prompt
initi
antivir
drug
treatabl
carv
well
earli
identif
treatment
direct
indirect
carvrel
complic
may
valu
addit
also
urgent
need
educ
patient
healthcar
giver
risk
transmiss
associ
carv
infect
especi
healthcar
worker
manag
workplac
health
safeti
infect
control
staff
administr
among
variabl
associ
higher
mortal
current
studi
confirm
lrtd
lymphopenia
remain
import
valid
risk
factor
mortal
carv
infect
allohct
set
besid
use
atg
show
direct
associ
mortal
overal
carv
limit
lrtd
find
unsurpris
atg
produc
lymphopenia
signific
delay
cell
immun
reconstitut
last
longer
year
stem
cell
infus
final
corrobor
valu
highrisk
isi
categori
predict
mortal
lrtd
caus
sever
carv
type
isi
develop
investig
md
anderson
cancer
center
predict
outcom
allohct
recipi
rsv
score
demonstr
valu
predict
lrtd
progress
mortal
context
influenza
respiratori
infect
rsv
howev
failur
differenti
risk
mortal
moderaterisk
lowrisk
isi
categori
indic
room
improv
meantim
highrisk
isi
categori
could
use
assess
sever
sever
carv
type
lrtd
involv
acknowledg
certain
limit
studi
inclus
sever
carv
type
use
three
differ
pcr
method
differ
minim
analyt
perform
nonetheless
studi
strength
merit
consider
notabl
use
molecular
test
prospect
data
collect
carv
survey
conclus
provid
evid
time
carv
infect
allohct
could
major
interest
due
consider
impact
outcom
prospect
studi
warrant
confirm
find
